UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________

FORM 8-K

______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~January~~June 2823, 2016

______________

AOXING PHARMACEUTICAL COMPANY, INC.

(Exact name of registrant as specified in its charter)

______________

Florida	0-24185	65-0636168
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

1098 Foster City Blvd., Suite 106-810, Foster City, CA 94404

(Address of Principal Executive Office) (Zip Code)

(646) 367 1747

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.~~02 Appointment~~07 Submission of ~~Certain~~Matters ~~Officers;~~to ~~Compensatory~~a ~~Arrangements~~Vote of ~~Certain~~Security ~~Officers~~Holders

On ~~January~~June 2823, 2016 ~~the Registrant's Board of Directors appointed Zheng James Chen to serve as the Registrant's Chief Financial Officer~~, ~~effective~~Aoxing onPharmaceutical ~~February 1~~Company, ~~2016~~Inc. ~~Guoan~~ ~~Zhang, who had been serving as Interim CFO, will remain with~~ (the ~~Registrant~~"Company") asheld ~~Senior~~its ~~Vice~~annual ~~President~~shareholder ~~for Finance~~meeting. ~~Information~~The ~~about~~shareholders ~~Dr.~~approved ~~Chen~~the ~~follows.~~following proposals:

~~Zheng~~Proposal ~~James~~1 ~~Chen~~- ~~was~~Election ~~employed from 2012 to 2016 as Chief Financial Officer~~ of ~~Origin Agritech Limited (NASDAQ: SEED), an agricultural biotechnology company headquartered in Beijing~~Directors. ~~From~~The ~~2008~~shareholders toelected ~~2012~~Zhenjiang ~~Dr. Chen was employed as an Investment Manager by the Abu Dhabi Investment Authority~~Yue, ~~which~~Jun ~~is the sovereign wealth fund for the government of Abu Dhabi. From 2003 to 2008~~Min, ~~Dr.~~Guozhu ~~Chen worked as an equity research analyst in three companies: Fulcrum Group Partners~~Xu, ~~BB&T~~Yang ~~Capital~~Li ~~Markets,~~ and ~~Morgan~~Yuelin ~~Joseph.~~Zhang ~~Previously, Dr. Chen was employed~~ as adirectors ~~technology~~to ~~license~~hold ~~manager~~office atuntil ~~Univation Technologies, a joint venture between ExxonMobil and Dow Chemical. Dr. Chen currently sits on~~ the ~~Board~~next ofannual ~~Directors~~meeting of, shareholders and isuntil ~~Chairman~~their ofsuccessors ~~the~~are ~~Audit~~duly ~~Committee for, China Finance Online (NASDAQ: JRJC)~~elected. HeA issummary ~~also Chairman~~ of ~~the~~votes ~~Board~~cast offollows Supervisors for Linjiang Chemical, which is listed on the New Third Board in China. Dr. Chen was awarded a Ph.D. in Chemical Engineering by the University of Connecticut in 1996, and an M.B.A. by New York University in 2004. Dr. Chen is 50 years old.below:

The Registrant has entered into a three year employment agreement with Dr. Chen. The agreement calls for an annual salary of $330,000. Dr. Chen is entitled to choose to receive common stock in lieu of salary for one or more periods of one, three or six months, with the shares valued at market price at the beginning of each such period The employment agreement also provides for a grant of options to purchase 300,000 shares at $.71 per share, vesting one-third per year during the term of the agreement.

Nominee	Votes for		Votes Withheld		Broker Non-Votes
Zhenjiang Yue		55,990,800		49,399		0
Jun Min		55,987,081		53,118		0
Guozhu Xu		55,977,992		62,207		0
Yang Li		55,987,120		53,079		0
Yuelin Zhang		55,976,950		63,249		0

~~Item~~Proposal 92 - To ratify the appointment of BDO China Shu Lun Pan Certified Accountants, LLP as independent registered public accounting firm of the Company for the fiscal year ending June 30, 2016.~~01 Financial~~ This ~~Statements~~proposal was approved with 56,029,450 shares voting for and ~~Exhibits~~10,249 shares voting against it (with 500,000 abstaining votes).

~~Exhibits~~Proposal 3 - To approve the 2016 Stock Incentive Plan. This proposal was approved with 55,821,050 shares voting for and 213,149 shares voting against it (with 6,000 abstaining votes).

10Proposal 4 -a ~~Aoxing~~To ~~Pharmaceutical~~ratify ~~Company~~the ~~CFO~~grant ~~Employment~~of ~~Agreement~~590,000 ~~dated~~stock ~~January~~options 28to certain employees identified in the proxy statement. This proposal was approved with 55,802,461 ~~2016~~shares voting for and 213,078 shares voting against it (with 24,660 abstaining votes).

Proposal 5 - To ratify the grant of 150,000 common shares to certain employees identified in the proxy statement. This proposal was approved with 55,809,075 shares voting for and 206,464 shares voting against it (with 24,660 abstaining votes).

Proposal 6 - To approve, on an advisory basis, the compensation paid to the Company's senior executive officers. This proposal was approved with 55,859,111 shares voting for and 160,986 shares voting against it (with 20,102 abstaining votes).

In addition, the shareholders provided the Board of Directors the shareholders' advisory vote on the frequency of shareholder advisory votes on executive compensation, as follows:

17,299,112 votes for an advisory vote on compensation every year.

27,911 votes for an advisory vote on compensation every two years.

38,704,284 votes for an advisory vote on compensation every three years.

8,892 votes abstained.

After the conclusion of the annual meeting of shareholders, the Company's Board of Directors held its annual meeting. At that meeting, after considering the shareholder advisory vote on the frequency of shareholder votes on executive compensation, the Board of Directors decided that, until the next required vote on the frequency of shareholder votes on compensation, the Company will include a shareholder vote on the compensation of executives in its proxy materials once every three years.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	Aoxing Pharmaceutical Company, Inc.
Date: February 1, 2016	By:	/s/ Zhenjiang Yue Zhenjiang Yue, Chief Executive Officer
Date: June 23, 2016	By:	/s/ Zhenjiang Yue Zhenjiang Yue, Chief Executive Officer

Filing Compare · AOXING PHARMACEUTICAL COMPANY, INC.